Cancer chemotherapy and G-CSF.

Mathematical model for G-CSF administration after chemotherapy.

Granulocyte-colony stimulating factor (G-CSF) is used clinically for treating chemotherapy-induced neutropenia (low neutrophil levels). Here we present a delay differential equation model for the regulation of neutrophil production that accounts for the effects of G-CSF. Using a combination of analysis and numerical simulations, we use this model to study the effects of delaying G-CSF treatment...

G-CSF treatment of chemotherapy induced neutropenia - Online supplement

Modelling human granulopoiesis under poly-chemotherapy with G-CSF support.

Cytotoxic drugs administered in polychemotherapy cause a characteristic neutropenic period depending on the schedule of the drugs, which can partly be prevented by G-CSF growth factor support. To quantify these effects and to gain a deeper insight into the dynamics of bone marrow recovery after such suppressing and stimulating disturbances, we construct a biomathematical compartment model of hu...

Comparison of Therapeutic G-CSF Cycles and Prophylactic G-CSF Cycles in Patients Receiving Paclitaxel and Carboplatin Combination Chemotherapy for Ovarian Cancer: A Retrospective Study Report

OBJECTIVE The aim of the present study was to investigate the differences between therapeutic granulocyte-colony stimulating factor (G-CSF) cycles and prophylactic G-CSF cycles in patients receiving paclitaxel and carboplatin combination chemotherapy for ovarian cancer. MATERIAL AND METHOD Medical records of 15 women who received paclitaxel and carboplatin combination chemotherapy for ovarian...

Primary or secondary G-CSF prophylaxis to support TAC chemotherapy in breast cancer?

editorial Primary or secondary G-CSF prophylaxis to support TAC chemotherapy in breast cancer? Taxanes and anthracyclines are two of the most active agents against breast cancer. Many trials with a positive outcome have recently been reported in the adjuvant setting. In the Cancer and Leukaemia Group B (CALGB) 9344 trial, 3121 women with node-positive breast cancer were randomly assigned to rec...